Evidence map›Paper›PMID 31570358›Full record

ArticleBMJ case reports2019

Acute intermittent porphyria: analgesia can be dangerous.

Carlos Dias Silva, José Eduardo Mateus, Carolina Teles, Teresa Vaio

Open access · bronzeAbstract readCase Reports
In one paragraph

Article in BMJ case reports, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.2field-weighted citation impact, top 47% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 4 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 1 institution in 1 country.

Carlos Dias SilvaDepartment of Internal Medicine, Centro Hospitalar e Universitario de Coimbra EPE, Coimbra, Portugal.ORCID http://orcid.org/0000-0003-3357-5591
José Eduardo MateusDepartment of Internal Medicine, Centro Hospitalar e Universitario de Coimbra EPE, Coimbra, Portugal.ORCID http://orcid.org/0000-0003-1506-152X
Carolina TelesDepartment of Internal Medicine, Centro Hospitalar e Universitario de Coimbra EPE, Coimbra, Portugal.
Teresa VaioDepartment of Internal Medicine, Centro Hospitalar e Universitario de Coimbra EPE, Coimbra, Portugal.
Hospitais da Universidade de Coimbra · PT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Acute intermittent porphyria (AIP) is a rare condition, a metabolic disorder of the haem biosynthesis. An acute crisis of AIP can present as a combination of symptoms, such as abdominal pain, autonomic dysfunction, hyponatremia, muscle weakness and neurological symptoms in the absence of others obvious causes. We report the case of a 53-year-old woman, who was previously diagnosed with AIP 5 weeks after therapeutic suspension has developed an acute disease exacerbation. During hospitalisation, further exacerbation has occurred after analgesia with metamizole. Glucose and hemin infusions resulted in slow improvement. Physical rehabilitation was crucial to peripheral polyneuropathy recovery. Taking into account the porphyrinogenic effect described for metamizole, this drug might have triggered the second attack. Clinical history was sufficient to suspect the diagnosis and to start the treatment immediately, preventing important sequelae.

Indexed as

Abdominal PainAnti-Inflammatory Agents, Non-SteroidalDipyroneDisease ProgressionFemaleGlucoseHeminHumansHyponatremiaInfusions, ParenteralMiddle AgedMuscle WeaknessPain ManagementPorphyria, Acute IntermittentTreatment OutcomeAnti-Inflammatory Agents, Non-SteroidalDipyroneGlucoseHemincontraindications and precautionsmetabolic disorderspainphysiotherapy (rehabilitation)safety

Identifiers

PMID31570358
PMCPMC6768370
OpenAlexW2977564708

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.